NurExone Expands U.S. Footprint with Boston Life Sciences Events Push
Event summary
- NurExone to participate in four major Boston life sciences events from September 22-25, 2026, featuring CEO Dr. Lior Shaltiel as a speaker.
- Company to present development programs and engage with investors, researchers, and industry participants.
- NurExone has entered into a non-exclusive investor relations agreement with RedChip for a two-week national television campaign.
- ExoPTEN, NurExone's lead therapeutic candidate, is advancing toward clinical development for acute spinal cord injury.
The big picture
NurExone's strategic push into the U.S. market comes as the biotech company seeks to establish a commercial platform and advance its lead therapeutic candidate, ExoPTEN. The participation in high-profile life sciences events underscores NurExone's focus on engaging with key stakeholders and positioning itself as a leader in exosome-based regenerative therapies. The company's recent memorandum of understanding with Made Scientific for U.S. manufacturing further highlights its commitment to scaling operations in the region.
What we're watching
- Clinical Validation
- How NurExone's participation in these events will impact investor confidence in its exosome therapeutics.
- Market Positioning
- Whether NurExone can leverage these engagements to secure financing or commercial partnerships.
- Regulatory Milestones
- The pace at which NurExone advances ExoPTEN toward clinical trials in the U.S. and Europe.
Related topics